SS
BOLT icon

SBI Securities’s Bolt Biotherapeutics BOLT Stock Holding History

SBI Securities’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501 Buy
130
+120
+1,200% +$563 ﹤0.01% 3030
2026
Q1 		$40 Hold
10
– – ﹤0.01% 3620
2025
Q4 		$55 Hold
10
– – ﹤0.01% 3555
2025
Q3 		$53 Hold
10
– – ﹤0.01% 3696
2025
Q2 		$58 Hold
10
– – ﹤0.01% 3686
2025
Q1 		$80 Hold
10
– – ﹤0.01% 3516
2024
Q4 		$107 Buy
+10
New +$121 ﹤0.01% 3434

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SBI Securities's BOLT Position: Q2 2026 in Review

SBI Securities increased its Bolt Biotherapeutics (BOLT) stake by 1,200% in Q2 2026, buying an estimated $563 and bringing the position to 130 shares worth $501. The position accounts for ﹤0.01% of the portfolio, ranked #3030.

SBI Securities first reported a position in BOLT in Q4 2024 and has held it in 7 quarters since. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • SBI Securities held 130 shares of Bolt Biotherapeutics worth $501 as of Q2 2026.
  • SBI Securities bought 120 Bolt Biotherapeutics shares in Q2 2026, an estimated $563.
  • Bolt Biotherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3030 holding.
  • SBI Securities first reported a position in Bolt Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.